Overall survival rate of patients with CML who initially respond but later progress on TKI therapy and acquire EVI1 overexpression is half compared to those without EVI1 expression48. The gene discussed is MECOM; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.